May 21, 2020 / 11:32 AM / 8 days ago

BRIEF-Health Canada Clears Appili Therapeutics' Phase 2 Clinical Trial Evaluating Favipiravir As A Prophylactic Agent Against Covid-19 Outbreaks

May 21 (Reuters) - Appili Therapeutics Inc:

* HEALTH CANADA CLEARS APPILI THERAPEUTICS’ PHASE 2 CLINICAL TRIAL EVALUATING FAVIPIRAVIR AS A PROPHYLACTIC AGENT AGAINST COVID-19 OUTBREAKS

* APPILI THERAPEUTICS - APPILI EXPECTS TRIAL RECRUITMENT TO BEGIN IMMINENTLY

* APPILI THERAPEUTICS - RESEARCHERS WILL ENROLL APPROXIMATELY 760 SUBJECTS, BOTH RESIDENTS AND STAFF, AT 16 LONG-TERM CARE HOMES (LTCHS) IN ONTARIO Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below